NCT00881946

Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 in Subjects With Any Hematologic Malignancy

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 73 (actual)
• Sponsor: Accenture · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.

Conditions

• Hematologic Malignancies

Interventions

Type	Name	Description
DRUG	GSK21110183	Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops

Timeline

• Start date: 2009-07-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2009-04-15
• Last updated: 2012-04-04

Locations

4 sites across 3 countries: Australia, Canada, South Korea